SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http: www.accessdata.fda.gov drugsatfda_docs label 2009 021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance - Media and Sport - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-06-20 11:12:30 Gastroenterology Exenatide Sitagliptin Glucagon-like peptide-1 Glimepiride Dipeptidyl peptidase-4 inhibitor Glucose tolerance test Anti-diabetic drugs Endocrine system Chemistry		SUPPLEMENTARY DATA Exenatide: The Investigator’s brochure from Eli Lilly and Company (http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf) indicates that the ‘mean apparent clearance Add to Reading List Source URL: care.diabetesjournals.org Download Document from Source Website File Size: 649,96 KB Share Document on Facebook

	Diabetes Numbers At-a-Glance 2009 DocID: 1rpk6 - View Document
	Microsoft Word - prediabetes data brieffinal DocID: 1r19H - View Document
	All About Pre-Diabetes Toolkit No. 1 What is pre-diabetes? Pre-diabetes is a condition that comes before type 2 diabetes. Blood glucose (sugar) levels are DocID: 1qEbS - View Document
	Clinical Practice Guidelines Adult Diabetes Mellitus Standards of Medical Care in Diabetes – 2016, American Diabetes Association Source Guideline DocID: 1ptxp - View Document
	Trial to Reduce IDDM in the Genetically at Risk TRIGR Family News Editor’s Corner Dear Study Families! DocID: 1fYQW - View Document